Neutralizing Complement C5a Protects Mice with Pneumococcal Pulmonary Sepsis

Abstract

Background Community-acquired pneumonia and associated sepsis cause high mortality despite antibiotic treatment. Uncontrolled inflammatory host responses contribute to the unfavorable outcome by driving lung and extrapulmonary organ failure. The complement fragment C5a holds significant proinflammatory functions and is associated with tissue damage in various inflammatory conditions. The authors hypothesized that C5a concentrations are increased in pneumonia and C5a neutralization promotes barrier stabilization in the lung and is protective in pneumococcal pulmonary sepsis. Methods The authors investigated regulation of C5a in pneumonia in a prospective patient cohort and in experimental pneumonia. Two complementary models of murine pneumococcal pneumonia were applied. Female mice were treated with NOX-D19, a C5a-neutralizing l-RNA-aptamer. Lung, liver, and kidney injury and the inflammatory response were assessed by measuring pulmonary permeability (primary outcome), pulmonary and blood leukocytes, cytokine concentrations in lung and blood, and bacterial load in lung, spleen, and blood, and performing histologic analyses of tissue damage, apoptosis, and fibrin deposition (n = 5 to 13). Results In hospitalized patients with pneumonia (n = 395), higher serum C5a concentrations were observed compared to healthy subjects (n = 24; 6.3 nmol/l [3.9 to 10.0] vs. 4.5 nmol/l [3.8 to 6.6], median [25 to 75% interquartile range]; difference: 1.4 [95% CI, 0.1 to 2.9]; P = 0.029). Neutralization of C5a in mice resulted in lower pulmonary permeability in pneumococcal pneumonia (1.38 ± 0.89 vs. 3.29 ± 2.34, mean ± SD; difference: 1.90 [95% CI, 0.15 to 3.66]; P = 0.035; n = 10 or 11) or combined severe pneumonia and mechanical ventilation (2.56 ± 1.17 vs. 7.31 ± 5.22; difference: 4.76 [95% CI, 1.22 to 8.30]; P = 0.011; n = 9 or 10). Further, C5a neutralization led to lower blood granulocyte colony-stimulating factor concentrations and protected against sepsis-associated liver injury. Conclusions Systemic C5a is elevated in pneumonia patients. Neutralizing C5a protected against lung and liver injury in pneumococcal pneumonia in mice. Early neutralization of C5a might be a promising adjunctive treatment strategy to improve outcome in community-acquired pneumonia. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New

Severe Acute Lung Injury Related to COVID‐19 Infection: A Review and the Possible Role for Escin

“…Further, Xin et al 72 described that escin could increase glucocorticoid receptor in the lung of animals, especially reversing the decrease of glucocorticoid receptor resulting from LPS, supporting the idea that the anti‐inflammatory effect of escin could involve the upregulation of glucocorticoid receptor with an increase of endogenous antioxidant activity. In a mouse model of pneumococcal pneumonia, a 4‐day administration of escin (1.8 mg/kg intravenously), significantly reduced lung inflammation, suggesting a role for escin as add‐on treatment 73,74 …”

Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics

“…Aptamers have also been developed to block C5a (Yatime et al, 2015;Hyzewicz et al, 2017) and C5aR1 (Kumar, 2018). A mouse study showed protection against pneumococcal sepsis using an aptamer blocking C5a (Müller-Redetzky et al, 2020), but the aptamers have not yet reached the clinic. 4.…”

Complement as driver of systemic inflammation and organ failure in trauma, burn, and sepsis

“…Concerning deployment of complement therapeutics during experimental sepsis, complement depletion [ 161 ], C1 inhibition [ 162 ], specific blockade of C5a [ 118 , 163 ], C5aR1 [ 164 ], genetic deficiency in C5 [ 165 ], or genetic absence of C6 [ 166 , 167 ] have been demonstrated to improve sepsis-induced pulmonary inflammation on a morphological and/or functional level.…”